Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (November 2019)
14 slides from Prescient Therapeutics's shareholder meeting presentation, Nov 19, 2019
Slide 1: AGM Overview 2019
For personal use only AGM OVERVIEW 2019 Prescient Therapeutics Limited (ASX: PTX) 19 November 2019
Slide 2: Disclaimer and safe harbor
Disclaimer and safe harbor Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private For personal use only Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: A (busy) year in review
A (busy) year in review • A successful A$9 million capital raising • Collaboration with a private US-based company to create supported by existing shareholders and several new formulations of our lead compound and significantly For personal use only leading US and Australian specialist life science
Slide 4: Once again tracking against prior year's objectives
Once again tracking against prior year’s objectives. Last year we said: For personal use only • Initiate the PTX-100 PK/PD study • Complete Phase 2 (part1) of PTX-200 in breast cancer ON TRACK FOR Q4 • Complete Phase 1b expanded cohort of PTX-200 in AML ON TRACK FOR Q4 • Complete Phase 1b PTX-200 in
Slide 5: Overcoming inevitable challenges
Overcoming inevitable challenges inherent in drug development, including: For personal use only • Prescient remains within budget, but it will be prudent to • Increasing headwinds with falling either migrate some US trials to Australia, and/or seek AUD:USD exchange rate investigator sponsored initia
Slide 6: Working in areas of significant business development interest
Working in areas of significant business development interest …and it’s not just us saying so: For personal use only Targeted Therapies: “Targeted therapeutic business development activity is exceptional… This area will stay hot but there has to be a targeted population to identify with a clear bene
Slide 7: Landscape continues to move in our favour
Landscape continues to move in our favour • 2019 saw several major industry developments in targeted therapies, validating our investment and strategy. For personal use only • There is no sign this industry trend will slow down. • Like these companies, Prescient’s targeted therapies target mutations
Slide 8: Ras mutations dominating industry headlines
Ras mutations dominating industry headlines For personal use only
Slide 9: Listed Ras peers
Listed Ras peers For personal use only Drug AMG-510 MRTX849 G12Di PTX-100 K-Ras Inhibits KRAS G12C KRAS G12C KRAS G12D N-Ras RhoA Phase Phase 1 Phase 1 Preclinical Phase 1b Market US $121 B US$3 B A$24 M cap 9 GOOGLE FI NANCE 22 OCTOBER 2019
Slide 10: Personalised Medicine Strategy: Targeted Therapies and beyond
Personalised Medicine Strategy: Targeted Therapies and beyond For personal use only Prescient/Carina collaboration Targeted Therapies CAR-T PTX-100 PTX-200 10 P E R S O N A L I S E D M E D I C I N E S F O R C A N C E R P A T I E N T S
Slide 11: What is CAR-T therapy?
What is CAR-T therapy? • Chimeric Antigen Receptor T-cell therapy For personal use only – the most personalised medicine! • Genetically modifying a patient’s own T-cells (a type of white blood cell that fights infection) by adding a new receptor (“CAR”) • Enables the new T-cell to recognise and atta
Slide 12: Targeted therapy/CAR-T therapy collaboration
Targeted therapy/CAR-T therapy collaboration For personal use only • Collaboration with private CAR-T company Carina Biotech • Seeking to address some of the current challenges of CAR-T therapy • Combines Prescient’s knowledge of targeted therapies with Carina’s cell therapies to improve CAR-T appro
Slide 13: Presentation summary
Presentation summary For personal use only ASX CODE: PTX Only ASX exposure to Ras • Another year of solid progress • PTX-200 in 3 studies; results out shortly • PTX-100 trial underway & uniquely positioned in hot Ras space • Both drugs have potential advantages over competitors’ approaches • Persona
Slide 14: Contact us
For personal use only Contact us Steven Yatomi-Clarke CEO & Managing Director steven@ptxtherapeutics.com +61 417 601 440 ptxtherapeutics.com . 14 P E R S O N A L I S E D M E D I C I N E S F O R C A N C E R P A T I E N T S
Prescient Therapeutics — Shareholder Meeting (November 2019) on 6ix